A Study of the C3 Inhibitor AMY-101 in Patients With ARDS Due to COVID-19 (SAVE)

Clinical trial NCT04395456 · UNKNOWN

Trial details

NCT number: NCT04395456
Sponsor: Amyndas Pharmaceuticals S.A.
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Acute Respiratory Distress Syndrome Due to SARS-CoV-2 Infection (Severe COVID19)

Start date: 2021-09-01
Primary completion: 2022-09-01
Enrollment: 144

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.